Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Antimicrobial Resistance

    NIAID Seeks Proposals for Broad Spectrum Biodefense Countermeasures

    By Global Biodefense StaffJuly 18, 2012
    Share
    Facebook LinkedIn Reddit Email

    National Institute of Allergy and Infectious Diseases (NIAID) has released a new Broad Agency Announcement (BAA) in support of the development of candidate therapeutic products for use in post-event settings following the intentional release of Category A, B, and C biothreat agents or in response to naturally occurring outbreaks of infectious diseases caused by pathogens in the same category.

    The funding opportunity specifically focuses on the development of promising biodefense therapeutic products with broad spectrum therapeutic activity, enabling mitigation of biological threats across a wide range or class of agents. There are a number of traditional threats for which effective treatments are either non-existent, of limited usefulness, or vulnerable to both naturally emerging and intentionally engineered antibacterial and antiviral resistance.

    “A limited number of anti-infectives with broad spectrum activity directed at common, invariable, and essential components of different classes of microbes could potentially be effective against both traditional and non-traditional threats,” states the announcement.  “This approach would allow a small number of drugs to replace dozens of pathogen-specific drugs for emergency use.”

    Agents of interest for broad-spectrum anti-bacterials include: Bacillus anthracis, Francisella tularensis, Yersinia pestis, Burkholderia pseudomallei, B. mallei, and Rickettsia prowazekii. For anti-virals, the target pathogens include: Ebola virus, Marburg virus, Variola major, Dengue virus, Venezuelan encephalitis virus, Western Equine encephalitis virus, Eastern Equine encephalitis virus and human influenza virus.

    Strategies to overcome bacterial and viral drug resistance could have immediate public health benefits of extending the utility of existing broad spectrum anti-infectives. Similarly, developing targeted immune response mechanisms could provide clinical utility when used alone or in combination with conventional anti-infectives.

    The solicitation also focuses on development of promising anti-toxins as biodefense therapeutic candidates, particularly small molecule therapeutics with anti-toxin activity. While bacteria that produce toxins may often be eliminated by the use of antibiotics, disease may still occur or may progress because of the presence of toxins produced by the pathogen. Targets supported under this effort include: Botulinum neurotoxin, Staphylococcus enterotoxin B, Bacillus anthracis Protective Antigen, Lethal Factor or Edema Factor, and ricin toxin.

    The activities supported through the BAA will allow candidate therapeutic countermeasures to progress through the product development pipeline toward licensure by the FDA with the eventual goal of stockpiling these medical countermeasures and associated technologies.

    Full details are available under Solicitation Number: BAA-NIAID-DMID-NIHAI2012149. The response deadline is October 1, 2012.

    Antimicrobials Antitoxins Antivirals BAA Botulinum Neurotoxin Ricin
    Share. Facebook LinkedIn Reddit Email
    Previous ArticlePanel Rejects Option for Keeping Biodefense Research on Plum Island
    Next Article Sequencing of 100,000 Pathogens to Help Solve Foodborne Outbreaks

    Related Stories

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.